Rare Voices Australia

Rare Voices Australia
Name	Rare Voices Australia
Type	Non-profit advocacy organization
Founded	2016
Location	Australia
Area served	Australia
Focus	Rare diseases, patient advocacy, policy

Rare Voices Australia is a national coalition advocating for Australians affected by rare, genetic and undiagnosed conditions. Founded in 2016, the organization engages with health agencies, charitable foundations, research institutes and international networks to influence policy, funding and service delivery for rare-condition communities.

History

Rare Voices Australia traces its origins to national and state patient groups that sought coordinated representation after the release of recommendations from the World Health Organization and regional rare-disease strategies such as the European Union Rare Disease Day initiatives. Early stakeholders included consumer groups linked to the National Health and Medical Research Council, state-based registries and charitable peaks that had previously engaged with inquiries like the Senate Community Affairs References Committee hearings. The formation drew on advocacy models from organizations such as EURORDIS and the Rare Diseases International alliance, aligning with Australian policy processes involving the Department of Health and Aged Care and state health departments. Over time, the coalition worked alongside research centres at institutions including the Garvan Institute of Medical Research, the Murdoch Children's Research Institute, and the Commonwealth Scientific and Industrial Research Organisation to translate clinical priorities into policy submissions to bodies such as the Medical Research Future Fund.

Mission and Activities

The mission centers on improving diagnosis, care and support for people with rare conditions through policy reform, community engagement and research translation. Core activities mirror advocacy strategies used by groups like the Australian Genomics Health Alliance and community peaks such as the Health Consumers' Council (WA), involving submissions to inquiries from the Parliament of Australia and consultations with agencies including the Therapeutic Goods Administration and the Pharmaceutical Benefits Advisory Committee. The organisation coordinates national awareness campaigns in parallel with observances like Rare Disease Day and liaises with philanthropic funders such as the Ian Potter Foundation and the Myer Foundation to mobilise resources for projects with clinical partners like the Royal Children's Hospital, Melbourne and the Royal Prince Alfred Hospital.

Governance and Funding

Governance arrangements reflect a coalition model with a board populated by representatives from member groups, clinicians and consumer leaders drawn from networks including the Australian Genomics Health Alliance and the Human Genetics Society of Australasia. Financial support combines philanthropic grants from entities such as the Ian Potter Foundation and the Paul Ramsay Foundation, project funding through the Medical Research Future Fund, and partnerships with research institutes like the Walter and Eliza Hall Institute of Medical Research. The organisation engages in policy advocacy during budget processes in the Parliament of Australia and provides submissions to statutory reviews undertaken by bodies such as the Australian Health Practitioner Regulation Agency. Accountability mechanisms include reporting to member organisations, audits aligned with the Australian Charities and Not-for-profits Commission and partnerships with peak bodies like Cancer Council Australia on shared governance issues.

Programs and Services

Programs focus on improving diagnostic pathways, expanding access to genomic testing and supporting peer networks. Initiatives have involved collaboration with laboratory networks such as NSW Health Pathology and clinical consortia like the Australian and New Zealand Inherited Cardiac Conditions Registry to pilot diagnostic strategies. Support services mirror those delivered by consumer organisations including Cure Our Kids and Kidney Health Australia, offering information, family support and links to specialist clinics at centres like the Royal Children's Hospital, Melbourne and the Children's Hospital at Westmead. Educational activities target clinicians, policymakers and community groups, including workshops modelled on training delivered by the Peter MacCallum Cancer Centre and webinars co-presented with the Genome Institute of Singapore-style partners. Research translation programs coordinate with the Murdoch Children's Research Institute and the University of Sydney to evaluate outcomes and inform health technology assessment processes at the Pharmaceutical Benefits Advisory Committee.

Advocacy and Impact

Advocacy accomplishments include influencing national strategies for rare diseases, contributing to submissions informing funding decisions by the Pharmaceutical Benefits Advisory Committee and engaging with parliamentary inquiries such as those hosted by the Senate Community Affairs References Committee. The organisation has amplified voices in national media outlets and collaborated with international actors like EURORDIS and Rare Diseases International to shape global policy dialogues influenced by the World Health Organization’s priorities. Outcomes cite improved access to genomic diagnostics in pilot jurisdictions, strengthened patient registries linked to initiatives at the Australian Genomics Health Alliance, and enhanced service coordination with state health systems including Queensland Health and Victorian Department of Health.

Partnerships and Collaborations

Rare-disease advocacy work depends on cross-sector partnerships with hospitals, research institutes, philanthropic organisations and international networks. Notable collaborators include the Murdoch Children's Research Institute, the Garvan Institute of Medical Research, the Walter and Eliza Hall Institute of Medical Research, the Australian Genomics Health Alliance, and international partners like EURORDIS and Rare Diseases International. Collaboration extends to state health services such as NSW Health, academic partners at the University of Melbourne and the University of Sydney, and funders including the Ian Potter Foundation and the Paul Ramsay Foundation. Engagement with regulatory bodies like the Therapeutic Goods Administration and advisory committees such as the Pharmaceutical Benefits Advisory Committee supports policy influence and program delivery across Australia.

Category:Health charities in Australia Category:Rare disease organizations